These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27545059)

  • 41. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
    Tarsin WY; Pearson SB; Assi KH; Chrystyn H
    Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Flow and inspiratory pressure characteristics of In-Check(tm) and training whistles].
    Kondo T; Tanigaki T; Kato S; Tazaki G; Watanabe H; Tsunoda T; Uruma T
    Arerugi; 2012 Jun; 61(6):813-9. PubMed ID: 22868521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful use of DPI systems in asthmatic patients--key parameters.
    Richter K
    Respir Med; 2004 Oct; 98 Suppl B():S22-7. PubMed ID: 15481285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes.
    Price DB; Román-Rodríguez M; McQueen RB; Bosnic-Anticevich S; Carter V; Gruffydd-Jones K; Haughney J; Henrichsen S; Hutton C; Infantino A; Lavorini F; Law LM; Lisspers K; Papi A; Ryan D; Ställberg B; van der Molen T; Chrystyn H
    J Allergy Clin Immunol Pract; 2017; 5(4):1071-1081.e9. PubMed ID: 28286157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes.
    Levy ML; Carroll W; Izquierdo Alonso JL; Keller C; Lavorini F; Lehtimäki L
    Adv Ther; 2019 Oct; 36(10):2547-2557. PubMed ID: 31478131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.
    Holmes MS; Seheult JN; O'Connell P; D'Arcy S; Ehrhardt C; Healy AM; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):247-53. PubMed ID: 25393346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dry powder inhalers - between the doctor and the patient.
    Emeryk A; Pirożyński M; Emeryk-Maksymiuk J
    Adv Respir Med; 2018; 86(1):44-52. PubMed ID: 29490421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhalation Profiles Through a Dry Powder Inhaler: Relation Between Inhalation Technique and Spirometric Measures.
    Dorosz A; Urbankowski T; Zieliński K; Michnikowski M; Krenke R; Moskal A
    J Aerosol Med Pulm Drug Deliv; 2021 Dec; 34(6):346-357. PubMed ID: 33877899
    [No Abstract]   [Full Text] [Related]  

  • 50. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
    Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
    Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis.
    Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Patzlaff A; Weimann B
    J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):156-163. PubMed ID: 30848695
    [No Abstract]   [Full Text] [Related]  

  • 52. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
    Henriet AC; Marchand-Adam S; Mankikian J; Diot P
    Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhaler technique maintenance: gaining an understanding from the patient's perspective.
    Ovchinikova L; Smith L; Bosnic-Anticevich S
    J Asthma; 2011 Aug; 48(6):616-24. PubMed ID: 21623690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy.
    Albertson TE; Bullick SW; Schivo M; Sutter ME
    Drug Des Devel Ther; 2016; 10():4047-4060. PubMed ID: 28008228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dry-powder inhalers in acute asthma.
    Selroos O
    Ther Deliv; 2014 Jan; 5(1):69-81. PubMed ID: 24341818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using acoustics to estimate inspiratory flow rate and drug removed from a dry powder inhaler.
    Holmes MS; Seheult J; Geraghty C; D'Arcy S; Costello RW; Reilly RB
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():6866-9. PubMed ID: 24111322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Asthma inhaler with feedback system provided better care and lower costs].
    Ahlbeck L
    Lakartidningen; 2014 Jan 29-Feb 4; 111(5):160. PubMed ID: 24624769
    [No Abstract]   [Full Text] [Related]  

  • 58. Daily inhaled flow profiles and drug release from dry powder inhalers in patients with bronchial asthma.
    Tajiri S; Kondo T; Tanigaki T; Hibino M; Asano K
    Respir Med; 2022 Sep; 201():106950. PubMed ID: 35963030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modeling of Inhalation Profiles Through Dry Powder Inhaler in Healthy Adults and Asthma Patients As a Prerequisite for Further
    Dorosz A; Urbankowski T; Zieliński K; Michnikowski M; Krenke R; Moskal A
    J Aerosol Med Pulm Drug Deliv; 2022 Apr; 35(2):91-103. PubMed ID: 34516926
    [No Abstract]   [Full Text] [Related]  

  • 60. In vitro evaluation of dry powder inhaler devices of corticosteroid preparations.
    Tamura G; Sakae H; Fujino S
    Allergol Int; 2012 Mar; 61(1):149-54. PubMed ID: 22189592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.